A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
PURPOSE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) approved for type 2 diabetes and overweight or obesity may affect alcohol drinking behavior. The present prospective observational study investigated hazardous alcohol drinking in patient…
Obesity is a well-established risk factor for perioperative morbidity, including periprosthetic joint infection (PJI) and unplanned readmission following total hip and knee arthroplasty. Glucagon-like peptide-1 (GLP-1) receptor agonists induce clinic…
BACKGROUND/OBJECTIVE: Hypothalamic obesity (HO) is a rare but severe form of obesity characterized by hypothalamic damage resulting in hyperphagia and decreased energy expenditure. Tumors involving the hypothalamus, most commonly craniopharyngiomas,…
INTRODUCTION: The mechanistic role of glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists (GLP-1RAs) in modulating brain functional activity has been inadequately examined. Mental disorders are characterized by dysregulated functional connect…
BACKGROUND: Repurposing glucagon-like peptide-1 (GLP-1) and GIP/GLP-1 receptor agonists (RAs) for idiopathic intracranial hypertension (IIH) represents an attractive alternative to current treatments, supported by evidence of potent metabolic effects…
CLINICAL QUESTION: What are the benefits and harms of medications for adults with type 2 diabetes at varied risks of cardiovascular and kidney related complications? CONTEXT: Emerging clinical trials of novel medications have demonstrated benefits on…
Obesity is a multifactorial, complex disease that is driven by genetic, biological, environmental, and behavioral factors. In this review, we explain the key contributors to obesity, limitations in current definitions, its relationship with cardiomet…
Tirzepatide is a unimolecular dual agonist of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, which is developed as once-weekly subcutaneous injection. It has been developed in two huge research…
INTRODUCTION: Tirzepatide is a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. GIP and GLP-1 are incretins promoting insulin release from pancreatic β-cells…
OBJECTIVE: Our objective was to model the potential cost-effectiveness of tirzepatide as an alternative to lifestyle modification (LSM) for the management of obesity and overweight. METHODS: An individual-level discrete event simulation was implement…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant cardiovascular (CV) benefits, particularly in patients with diabetes mellitus, but the safety and efficacy of different GLP-1 RAs across diverse populatio…
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the only type 2 diabetes medications that reduce cardiovascular disease and death, yet their availability in Medicaid is unc…
BACKGROUND: Incretin mimetics, especially dual/triple agonists, are effective for type 2 diabetes and obesity, though mechanisms remain unclear. This study applied PET using [Ga]Ga-DO3A-Exendin-4 and [Ga]S02-GIP-T4 to assess GLP-1R and GIPR occupancy…
OBJECTIVE: To compare the efficacy and safety of GLP-1 receptor agonists (GLP-1RAs), dual agonists (GLP-1RAs/GIP or GCGR), and retatrutide (GLP-1/GIP/glucagon) for weight loss in adults with overweight or obesity. METHODS: We conducted a systematic r…
Glucagon-like peptide-1 (GLP-1) receptor agonists now serve as therapeutic agents for cardiovascular diseases (CVDs) beyond their original use for treating type 2 diabetes mellitus (T2DM). This review combines molecular mechanisms with clinical evide…